title: [FULLERENE C60 INHIBITED FREE RADICAL AND DESTRUCTIVE PROCESSES IN CONNECTIVE TISSUE DURING ADJUVANT ARTHRITIS IN RATS].
abstract: The effects of fullerene C60 (FC60) on the level of free radical and destruction processes were studied in rats with experimental adjuvant arthritis (AA). It was shown the protective effect of FC60 during AA. The effect was accompanied by an increase of the antioxidant enzymes activity, superoxide dismutase in the liver (15.96 ± 0.38 μmol/kg x s) and in the kidneys (5.36 ± 0.27 μmol/kg x s) and catalase in the kidneys (9.56 ± 0.78 μmol/kg x s) and in the heart (2.26 ± 0.41 μmol/kg x s) in comparison to control group (43.83± 5.69%; 54.55 ± 6.18%; 11.68 ± 0.52 μmol/kg x s; 3.43 ± 0.47 μmol/kg x s; 4.77 ± 0.5 μmol/kg x s; 0.98 ± 0.12 μmol/kg x s accordingly). It was shown a protective effect of FC60 during AA directed on the depression of the destructive processes in connective tissue that was expressed through the reduction of the total collagenolitic activity level in cartilage (10.05 ± 0.06 μmol/g/min) and bone (11.21 ± 0.04 μmol/g/min) tissues, free hydroxyproline contents (1.54 ± 0.04 μg/ml) and alkaline phasphatase activity (1.24 ± 0,14 μmol/l x sec) in comparison to control group (11.91 ± 0.49 μmol/g/min; 13.19 ± 0.15 μmol/g/min; 2.25 ± 0.07 μg/ ml; 2.19 ± 0.24 μmol/l x sec accordingly). Taken together, these results accentuate the perspective of future investigations of action FC60 during rheumatoid arthritis as a feasible therapeutic agent.
authors.forename: T V
authors.initials: TV
authors.lastname: Mamontova
authors.forename: L E
authors.initials: LE
authors.lastname: Vesnina
authors.forename: M V
authors.initials: MV
authors.lastname: Mikityuk
authors.forename: N A
authors.initials: NA
authors.lastname: Bobrova
authors.forename: L A
authors.initials: LA
authors.lastname: Kutsenko
authors.forename: I L
authors.initials: IL
authors.lastname: Gordinskaya
authors.forename: I P
authors.initials: IP
authors.lastname: Kaidashev
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001842:Bone and Bones / Q000187:drug effects / Q000201:enzymology; D002356:Cartilage / Q000187:drug effects / Q000201:enzymology; D002374:Catalase / Q000378:metabolism; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005609:Free Radicals / Q000037:antagonists & inhibitors* / Q000378:metabolism; D037741:Fullerenes / Q000494:pharmacology*; D006909:Hydroxyproline / Q000378:metabolism; D007596:Joints / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016166:Free Radical Scavengers; D005609:Free Radicals; D037741:Fullerenes; D002374:Catalase; D013482:Superoxide Dismutase; D000469:Alkaline Phosphatase; C069837:fullerene C60; D006909:Hydroxyproline